The stock has gained 52.76 per cent over the last six months but remains down 1.84 per cent year-to-date (YTD).

A pharmaceutical stock gained nearly five percent, following news of a strategic acquisition. Investors reacted positively as the company moved to consolidate its stake in a key subsidiary, reflecting ...

HDT Bio requested at least $950 mln in damages India-based Emcure argued that court lacked jurisdiction Dec 4 (Reuters) - Generic drugmaker Emcure Pharmaceuticals (EMCU.NS), opens new tab convinced a ...

The initial public offering (IPO) of Emcure Pharmaceutical saw a strong response from the investors during the third and final day of the bidding process. After being fully subscribed more than 5 ...

HDT Bio accuses Indian drugmaker of stealing RNA tech Emcure allegedly planning to go public based on stolen tech (Reuters) - Seattle biopharma company HDT Bio Corp has sued Indian generic drugmaker ...

Emcure Pharmaceuticals saw its shares reach the upper circuit limit of 10 percent on Friday, May 23, 2025, continuing a rally for the third day in a row with an impressive overall gain of nearly 20 ...

Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy's ...

HDT’s first Brazilian patient receives a shot in its COVID-19 vaccine trial in that country. (HDT Bio Photo) Seattle vaccine company HDT Bio is seeking nearly $1 billion in a new lawsuit alleging that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

EMCURE PHARMACEUTICALS LTD - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information ...